We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Johannes Mann

Johannes F. E. Mann MD

Professor of Medicine, Friedrich Alexander University of Erlangen; Director, KfH Kidney Center, Munich, Germany; International Scholar, Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada

Johannes F. E. Mann, M.D., is a Professor of Medicine, Univ. of Erlangen-Nürnberg & Head, KfH Kidney Center, Munich, Germany. He is also International Scholar at Population Health Research Institute, McMaster University, Hamilton Canada. He is board-certified in Internal Medicine, Nephrology, Intensive Care and Pharmacology. His work focused initially on the physiology of the RAS in experimental animals and later the role of this system for diseases of the kidney & the heart. From there, his interest moved to the treatment of progressive kidney diseases. The latter included steering, adjudication and DSMB memberships in outcome trials, namely AIPRI, HOPE, MICRO-HOPE, HOPE-TOO, RENAL-ONTARGET, RENAL-TRANSCEND, ASCEND, DIABHYCAR, ORIGIN, LEADER, SONAR, SOUL, FLOW, DAPA-CKD. 

His scientific work includes about 270 original paper. His H-Index is 77; his citations rank among the top 25 of European nephrologists. Some of his papers, published in Nature, NEJM, Lancet, JAMA and Ann Int Med, were cited more than 2000 times, total citations are close to 40,000 according to Google Scholar.

Disclosures

Dr, Mann reports the following:
  • Committee member and speaker honoraria: AstraZeneca, Fresenius, Celgene, NovoNordisk, Sandoz, Relypsa, Vifor, Bayer
  • Speaker honoraria: Medice
  • Grant support: Europ Union, McMaster Univ Canada

Recent Contributions to PracticeUpdate:

  1. Novel Glucose-Lowering Drugs and Risk of AKI